CorMedix Raises Full-Year Guidance on Robust Q1 Results and Pipeline Momentum
Q1 2026 Performance: Revenue and Profit Surge as Product Demand Grows
CorMedix Therapeutics (NASDAQ: CRMD) delivered a notable first quarter in 2026, propelled by the continued outperformance of DefenCath and the successful integration of its acquired Melinta portfolio. Total net revenue for Q1 leapt to $127.4 million—more than triple the $39.08 million reported in the same period last year.
Both net income and adjusted EBITDA reflected this growth, at $38.6 million and $70 million, respectively. DefenCath contributed $97.5 million in revenue, benefiting from increased utilization among outpatient dialysis customers as well as a one-time $9 million positive adjustment in sales allowances. Melinta’s anti-infective products added $29.9 million to the top line.
| Q1 2026 ($M) | Q1 2025 ($M) | % Change |
|---|---|---|
| Net Revenue: 127.43 | 39.08 | +226% |
| Net Income: 38.60 | 20.64 | +87% |
| Adjusted EBITDA: 69.98 | 23.64 | +196% |
| EPS (Diluted): 0.43 | 0.30 | +43% |
| Cash & Cash Equiv: 178.09 | 144.84 | +23% |
Guidance Lifted: Full-Year Targets Move Higher on Positive Trends
The company boosted its full-year 2026 outlook, now guiding for net revenue between $325 million and $345 million, and adjusted EBITDA between $115 million and $135 million. This upward revision signals confidence in both ongoing product demand and upcoming pipeline milestones.
CEO Joseph Todisco credited the momentum to core market adoption of DefenCath and ongoing investments in late-stage development assets, such as REZZAYO for fungal prophylaxis. Notably, CorMedix’s cash position improved to $178.1 million at the end of March, providing ample financial flexibility for both reinvestment and potential business development.
Pipeline Update: Late-Stage Programs Advance, Regulatory Readouts Loom
CorMedix unveiled positive topline results from its Phase 3 ReSPECT trial evaluating REZZAYO for the prophylaxis of invasive fungal infections in allogeneic stem cell transplant patients—a key area of unmet need. The company anticipates submitting a supplemental NDA to the FDA in the second half of 2026, which, if approved, could enable a broader commercial launch in 2027.
Meanwhile, the TPN (total parenteral nutrition) indication for DefenCath is progressing through Phase 3 enrollment, with new study sites and protocol amendments designed to accelerate patient recruitment and strengthen future revenue streams.
Expense Growth Tied to Portfolio Expansion and R&D
Costs escalated in the quarter, with total operating expenses up 139% to $41.46 million, reflecting the full integration of Melinta. R&D expenses rose to $7.21 million, driven by increased clinical trial activity and personnel as CorMedix ventures into new therapeutic indications. Sales and marketing, and G&A expenses also saw substantial increases as the company scales its commercial and administrative operations.
| Q1 2026 Opex Category ($M) | Q1 2025 ($M) | % Change | |
|---|---|---|---|
| R&D | 7.21 | 3.19 | +126% |
| Selling & Marketing | 12.53 | 4.47 | +180% |
| G&A | 21.72 | 9.69 | +124% |
| Total Opex | 41.46 | 17.36 | +139% |
Investor Takeaway: Upbeat Financials Set Stage for Growth, But Risks Remain
CorMedix’s first-quarter results highlight significant progress both operationally and financially. With strong uptake for DefenCath, promising pipeline catalysts ahead, and increased full-year guidance, the company is positioned for continued growth. Investors should note, however, that clinical, regulatory, and competitive risks persist—especially as product launches and pivotal trials continue to unfold. Management’s upcoming conference call may provide further color on strategic priorities and anticipated milestones for the remainder of 2026.
For those tracking the next phase of CorMedix’s story, key areas to watch include the FDA submission for REZZAYO, trends in DefenCath usage post-TDAPA expiration, and execution on accelerated Phase 3 trial enrollment. The company’s evolving product mix and balance sheet strength suggest both opportunity and volatility as it navigates its next stage of growth.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI